gene-editing - International Biopharmaceutical Industry

news

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Dive Brief: Intellia Therapeutics, a leading developer of CRISPR-based medicines, on Thursday said it will buy privately held Rewrite Therapeutics for $45 million,...

6 February 2022 news gene-editing | Intellia

Continue Reading →

news

Beam gets green light to begin first clinical test of base editing

Gene editing's promise is clearest, and perhaps closest, in sickle cell disease, a hereditary condition characterized by deformed, or "sickled," red blood cells that ...

15 November 2021 news Beam | clinical test

Continue Reading →

news

Moderna, teaming with a startup, wades further into gene editing

Before it rose to prominence as a vaccine maker, Moderna's original ambitions were to use its messenger RNA technology — a way to prompt the body's cells to produce h...

8 November 2021 news Biotech | gene-editing

Continue Reading →

news

Vertex aligns with another CRISPR gene editing startup

Mammoth's evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to detect and diagnose dise...

29 October 2021 news CRISPR | drugmaker

Continue Reading →

news

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company's estimates, can treat about 90% of the patient po...

27 August 2021 news Biotech | cystic fibrosis

Continue Reading →

news

Oxford Genetics signs licensing agreement with Aldevron to market lentiviral packaging plasmids

Oxford Genetics, a leading innovator of biopharmaceutical technologies, has signed a licensing agreement with world-class service organization, Aldevron to bring to m...

4 February 2019 news discovery and development | gene therapy

Continue Reading →

news

Vertex, CRISPR gene-editing therapy hit with clinical hold

U.S. regulators have placed a clinical hold on CRISPR Therapeutics' lead candidate, spurring a double-digit drop in the Swiss biotech's stock value by Thursday mo...

1 June 2018 news clinical | CRISPR

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Beam gets green light to begin first clinical test of base editing

Moderna, teaming with a startup, wades further into gene editing

Vertex aligns with another CRISPR gene editing startup

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Oxford Genetics signs licensing agreement with Aldevron to market lentiviral packaging plasmids

Vertex, CRISPR gene-editing therapy hit with clinical hold

International Biopharmaceutical Industry